FORM D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

GEO Mall Processing Section

JAN 18 2008

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D,

SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

1330029

OMB APPROVAL			
OMB NUMBER:	3235-0076		
Expires:	April 30, 2008		
Estimated average burder	1		
hours per response	16.00		

	SEC	CUSE ONLY
Prefix		Serial
	DAT	E RECEIVED

Name of Office (C) check if this is an amendment and	name has changed, and indicate change.)	•	
Convertible Promissory Notes and Warrants			
Filing Under (Check box(es) that apply): □ Ru Type of Filing: ■ New Filing □ Amendment	ile 504 □ Rule 505 ■ Rule 506 □ Section	4(6) 🗆 ULOE	
Type of Fining. a few Fining D American			reasur marer nêtir danne krast (IAD) (1814 Billé Mil) (48)
	A. BASIC IDENTIFICATION DATA	A.	188, KE 80101 98/9 87/10 1188/9 8001 18/18 81/10 1/9/4 81/16
Enter the information requested about the issuer			
Name of Issuer (□ check if this is an amendment and na	ime has changed, and indicate change.)		08021863
Ivrea Pharmaceuticals, Inc.			
Address of Executive Offices (Number and Street,	, City, State, Zip Code)	Telephone Number (Inclu	iding Area Code)
216 Ricciuti Drive, Quincy, MA 02169		617-376-2491	
Address of Principal Business Operations (if different from Executive Offices)	Number and Street, City, State, Zip Code)	Telephone Number (Inch	iding Area Code)
Brief Description of Business:			PROCESSED
Specialty pharmaceuticals company			PHOCESSED
Type of Business Organization			JAN 2 5 2000
■ corporation □	l limited partnership, already formed	other (please specify):	2 0 2000
□ business trust □	limited partnership, to be formed		THOMSON
	Month Year		- FINANCIAL
Actual or Estimated Date of Incorporation or Organizati Jurisdiction of Incorporation or Organization: (Enter two		□ Estimated	

GENERAL INSTRUCTIONS

Federal

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

DE

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA		
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
		•			
Lynch, Daniel S. Business or Residence Address	(Number and	Street, City, State, Zip Co	vde)		
Dasmos of Residence / Idaless	(ivamour and	onton, only, bune, bip oo	,		
c/o Ivrea Pharmaceuticals, Inc., 216 Ri					
Check Box(es) that Apply:	C Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Cattaneo, Maurizio					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Ivrea Pharmaceuticals, Inc., 216 Ri	asiuti Deiva Or	ines MA 02160			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		Beneficial Owner	B Excedite officer		a central and of Managing I water
,					
SoleRx LLC Business or Residence Address	Olymber and S	Street City State Zin Co.	da)		
Business of Residence Address	(Number and 2	Street, City, State, Zip Co	ue)		
c/o Ivrea Pharmaceuticals, Inc., 216 Ri	cciuti Drive, Qu	incy, MA 02169			
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Barrett, Peter					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
-/- Ad 1/ Pd VI I D 000 1		ies 220 Waleham MA	02451		
c/o Atlas Venture Fund VI, L.P., 890 W Check Box(es) that Apply:	Promoter □	☐ Beneficial Owner	□ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		Li Benenciai Owner	L Executive Officer	- Director	D General and of Managing Farther
· · · · · · · · · · · · · · · · ·					
Orlow, Seth Business or Residence Address	(Alumbar and	Street, City, State, Zip Co	da)		
business of Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Ivrea Pharmaceuticals, Inc., 216 Ri	cciuti Drive, Qu	incy, MA 02169			
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Garcia, Francisco					
Business or Residence Address	(Number and	Street, City, State, Zip Co	xde)		
c/o Easton Hunt Capital Partners, L.P.	7/7 Thind A	di El N V	L NS/ 10015		
Check Box(es) that Apply:	Promoter	□ Beneficial Owner	Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		- Deficient Owner	D Excent Contect	- Director	D General and of Managing Farmer
,					
Greenberg, Myles Business or Residence Address	(Alamban and	Street, City, State, Zip C	-4-2		
Business of Residence Address	(Number and	Street, Chy, State, Zip C	ode)		
c/o CHL Medical Partners II, L.P., 105	5 Washington I	Blvd., Stamford, CT 069	01		•
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	1				
Silverman, Scott					
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
-t- Adla - Vardana Farad VIII D. 600 V	V2 C4 C-	120 W-M NA	02451		
c/o Atlas Venture Fund VI, L.P., 890 V Check Box(es) that Apply:	Promoter □	■ Beneficial Owner	□ Executive Officer	Director	C General and/or Managing Postner
Full Name (Last name first, if individual)		= Denencial Owner	D EXCERNAC OFFICEL	□ Director	☐ General and/or Managing Partner
,		•			
Easton Hunt Capital Partners, L.P.	01. 1	C+ C': C: 2' 2			
Business or Residence Address	(Number and	Street, City, State, Zip C	oděj		
767 Third Avenue, 7th Floor, New York	ωNY 10017				

A. BASIC IDENTIFICATION DATA					
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) Atlas Venture Fund VI, L.P.	•				
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
890 Winter Street, Suite 320, Waltham,	•				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
CHL Medical Partners II, L.P. Business or Residence Address	(Number and 5	Street, City, State, Zip Co	ide)		
1055 Washington Blvd., Stamford, CT 0		moot, enty, biato, zip oo	ac)		
Check Box(es) that Apply:	☐ Promoter	Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	 	. ,, ,, ,,			
Kelly, Joseph					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive. Ou	incv. MA 02169			
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				-	
Hensby, Christopher Business or Residence Address (Number and Street, City, State, Zip Code)					
Business or Residence Address (Number and Street, City, State, Zip Code)					
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive, Qu	incy, MA 02169			
Check Box(es) that Apply:	D Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					THE STATE OF THE S
Wakan Miskad					
Kobos, Michael Business or Residence Address	(Number and S	Street City State Zin Co	de)		
Business or Residence Address (Number and Street, City, State, Zip Code)					•
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive, Qu	incy, MA 02169			
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
	•		,		
Check Box(es) that Apply:	- D	= D	5.5 × 1 × 0.5 ×	5 D'	- Constant Marini Pari
	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	□ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	- 1 tomoter	a beneficial Owlict	D Executive Officer	- Diator	D General andor Managing Farther
rome (Last mane mot, ii marridum)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		

•

.

B. INFORMATION ABOUT OFFERING							
	Yes	No					
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	0					
_	• (
2.	What is the minimum investment that will be accepted from any individual?	S <u>n/a</u> Yes	No				
3.	Does the offering permit joint ownership of a single unit?	, ws	. 110				
4.							
Full l	Name (Last name first, if individual)						
			 				
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	ne of Associated Broker or Dealer						
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers						
	(Check "All States" or check individual States)	All States					
_ [A [] _ [] _ [] _	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]				
Full	name (Last name first, if individual)						
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	ne of Associated Broker or Dealer						
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers						
	(Check "All States" or check individual States)	All States					
_ [1 _ [1 _ [1	IL]	_ (HI) _ [MS] _ [OR] _ [WY]	_ (ID) _ [MO] _ (PA) _ (PR)				
Full	Name (Last name first, if individual)						
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	ne of Associated Broker or Dealer						
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		-				
	(Check "All States" or check individual States)	All States					
_ [1 _ [1	AL] _[AK] _[AZ] _[AR] _(CA] _[CO] _[CT] _[DE] _[DC] _[FL] _[GA] IL] _[IN] _[IA] _[KS] _[KY] _[LA] _[ME] _[MD] _[MA] _[MI] _[MN] MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK] RI] _[SC] _[SD] _[TN] _[TX] _[UT] _[VT] _[VA] _[WA] _[WV] _[WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]				

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box cand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Aiready Sold
	Type of Security		
	Debt	\$	s
	Equity	\$	\$
	□ Common □ Preferred		
	Convertible Securities (including warrants)	\$_1,000,000	\$500,000
	Partnership Interests	\$	s
	Other (Specify Warrants)	s <u> </u>	s <u> </u>
	Total	\$ 1,000,000	\$500,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	6	\$ 500,000
	Non-accredited Investors		s
	Total (for filings under Rule 504 only)		<u> </u>
	Answer also in Appendix, Column 4, if filing under ULOE		J
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	Type of Security	Dollar Amount Sold
	Type of offering	Society	00.0
	Rule 505		\$
	Regulation A		\$
	Rule 504		S
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	n	s
	Printing and Engraving Costs		\$
			£ 20,000
	Legal Fees		\$20,000
	Accounting Fees	ם	\$
	Engineering Fees	۵	\$
	Sales Commissions (specify finders' fees separately)	0	s
	Other Expenses (identify)		S
	Total	_	\$ 20,000

	C, OFFERING PRICE, NUMBER OF INVESTORS, EXP	ENSES AN	D USE OF PROCEEDS		
	b. Enter the difference between the aggregate offering price given in response to Part C = 0 and total expenses furnished in response to Part C = Question 4.a. This difference is the "adjusted gross proceeds to the issuer."			s _	980,000
5.	Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to for each of the purposes shown. If the amount for any purpose is not known, furnish an est and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above.	timate			
	·		Payments to Officers, Directors. & Affiliates		Payments To Others
	Salaries and fces		\$		S
	Purchase of real estate	D	S		s
	Purchase, rental or leasing and installation of machinery and equipment	Ö	\$	O	s
	Construction or leasing of plant buildings and facilities		\$	CJ	S
	Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a	0	s	a	s
	Repayment of indebtedness	_	5	_	<u> </u>
	• •	а	s		\$ 980,000
	Working capital	G	· · · · · · · · · · · · · · · · · · ·	-	\$ <u></u>
	Other (specify):	. 0	3	G	<u> </u>
			\$	0	s
	Column Totals		S0		\$980,000
	Total Payments Listed (column totals added)		= \$	980,000	_
•	D. FEDERAL SIGNATU	JRE			
an	e issuer has duly caused this notice to be signed by the undersigned duly authorized person. undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon values are investor pursuant to paragraph (b)(2) of Rule 502.	ff this notice written reque	is filed under Rule 505, the	following an furnished	signature constitutes I by the issuer to any
	uer (Print or Type) The Pharmaceuticals, Inc.	1	Date January // , 2000	В	
	Jun 1	<u>~ - </u>			

ATTENTION

Title of Signer (Print or Type)

President and Chief Executive Officer

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)



Name of Signer (Print or Type)

Daniel S. Lynch

1